Does DARATUMUMAB Cause Malignant neoplasm progression? 83 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 83 reports of Malignant neoplasm progression have been filed in association with DARATUMUMAB (DARZALEX). This represents 0.3% of all adverse event reports for DARATUMUMAB.
83
Reports of Malignant neoplasm progression with DARATUMUMAB
0.3%
of all DARATUMUMAB reports
25
Deaths
19
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DARATUMUMAB?
Of the 83 reports, 25 (30.1%) resulted in death, 19 (22.9%) required hospitalization, and 6 (7.2%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DARATUMUMAB. However, 83 reports have been filed with the FAERS database.
What Other Side Effects Does DARATUMUMAB Cause?
Plasma cell myeloma (2,980)
Infusion related reaction (2,557)
Off label use (2,494)
Pneumonia (1,450)
Neutropenia (1,351)
Drug ineffective (1,110)
Thrombocytopenia (1,089)
Death (1,088)
Pyrexia (1,032)
Dyspnoea (996)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DARATUMUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
DARATUMUMAB vs DARATUMUMAB\HYALURONIDASE-FIHJ
DARATUMUMAB vs DARBEPOETIN ALFA
DARATUMUMAB vs DARIDOREXANT
DARATUMUMAB vs DARIFENACIN HYDROBROMIDE
DARATUMUMAB vs DAROLUTAMIDE